Jalandhar Online

Glioblastoma Pipeline Insight and Emerging Therapies by DelveInsight

 Breaking News
  • No posts were found

Glioblastoma Pipeline Insight and Emerging Therapies by DelveInsight

May 18
05:15 2021
Glioblastoma Pipeline Insight and Emerging Therapies by DelveInsight

Glioblastoma Pipeline” report has been added to DelveInsight

Glioblastoma Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of Glioblastoma Pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

Glioblastoma Overview

Glioblastoma is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed.

Glioblastoma Pipeline Insights: Overview

“Glioblastoma multiforme (GBM) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market. A detailed picture of the Glioblastoma multiforme (GBM) pipeline landscape is provided, which includes the disease overview and Glioblastoma multiforme (GBM) treatment guidelines. The assessment part of the report embraces in-depth Glioblastoma multiforme (GBM) commercial assessment and clinical assessment of the Glioblastoma multiforme (GBM) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma multiforme (GBM) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Request free sample copy- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight

 

Glioblastoma Pipeline: Regions Covered

  • Global

 

Glioblastoma key Players

  • Genentech
  • Merck
  • And many others

 

Glioblastoma Drugs

  • Avastin
  • Temodar/Temodal
  • And many others

 

Glioblastoma Treatment

Treatment regime for GBM majorly involves a combination of surgery, chemotherapy (bevacizumab, temozolomide), radiation, or stereotactic radiosurgery. Surgery is the mainstay treatment for GBM and its primary objective is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function.

 

Glioblastoma Pipeline Report

GBM is the most common and aggressive type of primary brain tumor in humans, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumours. GBM can present with focal or generalized signs due to mass effect, parenchymal infiltration and destruction. Neurological symptoms of GBM include headache that tends to worsen in the morning, vomiting, nausea, seizures, cognitive dysfunction, speech problems (difficulty in finding right words), vision problems (abnormal eye movement), etc.

 

Major Glioblastoma Treatment options

  • Radiation Therapy (X-rays, Gamma rays or Photons)
  • Surgery (Craniotomy, Awake craniotomy, Debulking surgery, Skull base surgery, Visualase and Kyphoplasty)
  • Others (Targeted Therapies, Immunotherapies and Tumour-Treating Fields (TTF))
  • Chemotherapy (Temozolomide, Bevacizumab, Lomustine, etc.)

 

Glioblastoma Report Highlights

  • Certain analysis of the numerous genetic abrasions found with GBM patients suggests that the genetic lesions are grouped into three main signalling pathways, including receptor tyrosine kinase/RAS/PI3K) which is altered in almost 88% of GBMs, P53 pathway, in 87% of GBMs and RB signalling pathway; altered in approximately 78% of GBMs.
  • Recent findings in GBM have proposed that there may exist a 3rd major category of GBM, different from primary and secondary GBM on the basis of mutation in the histone H3F3 gene.

 

Request free sample copy- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight

 

Following is the Table of content

1. Report Introduction

2. Glioblastoma multiforme (GBM) 

3. Glioblastoma multiforme (GBM) Current Treatment Patterns

4. Glioblastoma multiforme (GBM) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Glioblastoma multiforme (GBM) Late Stage Products (Phase-III)

7. Glioblastoma multiforme (GBM) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Glioblastoma multiforme (GBM) Discontinued Products

13. Glioblastoma multiforme (GBM) Product Profiles

14. Glioblastoma multiforme (GBM) Key Companies

15. Glioblastoma multiforme (GBM) Key Products

16. Dormant and Discontinued Products

17. Glioblastoma multiforme (GBM) Unmet Needs

18. Glioblastoma multiforme (GBM) Future Perspectives

19. Glioblastoma multiforme (GBM) Analyst Review  

20. Appendix

21. Report Methodology

 

What are the key questions?

  • What are the current options for Glioblastoma multiforme (GBM) treatment?
  • How many companies are developing therapies for the treatment of Glioblastoma multiforme (GBM)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Glioblastoma multiforme (GBM)?
  • How many Glioblastoma multiforme (GBM) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Glioblastoma multiforme (GBM)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Glioblastoma multiforme (GBM) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Glioblastoma multiforme (GBM)? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Glioblastoma multiforme (GBM) therapies?
  • What are the clinical studies going on for Glioblastoma multiforme (GBM) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Glioblastoma multiforme (GBM)?
  • How many patents are granted and pending for the emerging therapies for the treatment of Glioblastoma multiforme (GBM)?

 

Glioblastoma Research Methodology

The objective of updating DelveInsight coverage is to ensure that it represents the most up-to-date vision of the industry possible. The DelveInsight is a fully integrated solution for comprehensive intelligence on various pharmaceutical products, both in the market and in the pipeline, across the globe.

About DelveInsight

DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of the Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/